( CAMBRIDGE Mass.--(BUSINESS WIRE)--Jun ...)Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its,Ghrelin Antagonist Program at the American Diabetes Association's,Annual Meeting,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - Elixir Pharmaceuticals, Inc., today announced the presentation of two sets of preclinical data demonstrating that ghrelin antagonism may be a potential method for future treatment of a range of metabolic disorders. These data demonstrated a variety of beneficial metabolic effects, notably decreasing body weight, improvements in blood glucose and insulin levels, and reductions in fatty liver. The data were presented in poster sessions on Sunday, June 24th, during the American Diabetes Association's 67th Annual Scientific Sessions meeting, being held in Chicago, IL. Elixir is focused on the development of drugs to treat and prevent metabolic disease, as well as prevent age-related diseases, based on targets identified in the pathways regulating aging.

Ghrelin, which has been identified as a key metabolic regulator, is known to stimulate appetite and food consumption and is believed to play a key role in metabolism and energy storage. A naturally occurring hormone produced in the stomach, ghrelin is believed to act primarily at the level of the hypothalamus in the brain, which governs metabolism.

Elixir scientists have previously demonstrated that, compared to normal (control) mice, ghrelin receptor (GhrR) knockout mice resist the development of diabetes and obesity associated with a high-fat diet. After fifteen weeks of eating a high fat diet the normal (control) mice gained 10% more weight than GhrR knockout mice. Importantly, the knockout mice also had significantly lower blood glucose, insulin and HbA1c levels. These results illustrate the knockout mice resist the development of type 2 diabetes.

In the first poster Elixir presents data in which scientists compared the results of the GhrR knockout mice to those obtained with mice treated twice a day for up to 56 days with one of Elixir's potent, small molecule, oral GhrR antagonists. As with the Gh
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
2. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)